



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 12/02/2022 06:00
Last Report Issued 06/27/2022 14:35

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2532SP
Patient ID 2532SP
Chain 22001675
DOB Not Given
Sex Not Given
Workorder 22001675
Received 06/24/2022

Lab ID 22001675-001
Matrix Serum or Plasma
Patient Name 2532SP
Patient ID 2532SP
Container Type Black Cap Glass Container

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Results were removed from report on 06/27/2022.

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2532SP Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Teriflunomide (Pre-Pregnancy)	20	ng/mL	5.0	
-------------------------------	----	-------	-----	--

Synonym(s): Leflunomide Metabolite

Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is a metabolite of leflunomide.

Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL.

The drug carries a black box warning for hepatotoxicity and pregnancy.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.